Stuart Hughes, Pathios Therapeutics CEO
Bristol Myers pitches in to Pathios’ $25M Series B for GPCR inhibitor
Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
